Dow Strengthens Affinisol Portfolio for Drug Formulators
New polymers from Dow presented at CPhI 2014 help maximize a pharmaceutical product's solubilization performance.
Poorly soluble drug candidates can now get some help from Dow’s new polymers, which are designed to address the solubilization performance requirements of a pharmaceutical company’s APIs in spray-dried dispersion (SDD) and hot-melt extrusion (HME) formulations.
Dow’s solution for SDD is Affinisol HPMCAS (Hypromellose Acetate Succinate), a range of polymers that help maintain stable solid dispersions and inhibit API crystallization. The product offers polymer-tailoring options to maximize solubilization.
For HME formulations, Dow offers Affinisol HPMC (Hyromellose), a next-generation crystallization inhibitor that can be extruded over a wide range of temperatures without the use of plasticizers. Because of its low glass transition temperature, the product “provides drug formulators with new capabilities to formulate amorphous solid dispersions and controlled release profiles via extrusion processes,” according to a press release.
Source:
Dow
FDA Approves First Treatment for Rare Lipid Storage Disease Cerebrotendinous Xanthomatosis
February 24th 2025Cerebrotendinous xanthomatosis, or CTX, is a metabolic disorder caused by a gene mutation that results in a deficiency of an important enzyme in the ability of the human body to break down fats.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
